- Home
- XOMAP vs WDC Comparison
XOMAP vs WDC Comparison
Compare XOMAP & WDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- WDC
- Stock Information
- Founded
- XOMAP N/A
- WDC 1970
- Country
- XOMAP United States
- WDC United States
- Employees
- XOMAP 13
- WDC N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- WDC Electronic Components
- Sector
- XOMAP Health Care
- WDC Technology
- Exchange
- XOMAP Nasdaq
- WDC Nasdaq
- Market Cap
- XOMAP N/A
- WDC N/A
- IPO Year
- XOMAP N/A
- WDC N/A
- Fundamental
- Price
- XOMAP $26.08
- WDC $62.53
- Analyst Decision
- XOMAP
- WDC Buy
- Analyst Count
- XOMAP 0
- WDC 21
- Target Price
- XOMAP N/A
- WDC $89.42
- AVG Volume (30 Days)
- XOMAP N/A
- WDC 5.7M
- Earning Date
- XOMAP N/A
- WDC 10-24-2024
- Dividend Yield
- XOMAP N/A
- WDC N/A
- EPS Growth
- XOMAP N/A
- WDC N/A
- EPS
- XOMAP N/A
- WDC 0.99
- Revenue
- XOMAP N/A
- WDC $14,348,000,000.00
- Revenue This Year
- XOMAP N/A
- WDC $31.62
- Revenue Next Year
- XOMAP N/A
- WDC $10.73
- P/E Ratio
- XOMAP N/A
- WDC $63.27
- Revenue Growth
- XOMAP N/A
- WDC 26.61
- 52 Week Low
- XOMAP N/A
- WDC $46.05
- 52 Week High
- XOMAP N/A
- WDC $81.55
- Technical
- Relative Strength Index (RSI)
- XOMAP 52.06
- WDC 39.19
- Support Level
- XOMAP $25.72
- WDC $62.30
- Resistance Level
- XOMAP $26.00
- WDC $71.23
- Average True Range (ATR)
- XOMAP 0.18
- WDC 1.82
- MACD
- XOMAP -0.03
- WDC -0.64
- Stochastic Oscillator
- XOMAP 49.64
- WDC 6.44
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.